werewolftx.com - HOWL Real Price to Acquire Entire Company

werewolftx.com (HOWL) - corporate logo

This chart of Werewolf Therapeutics (HOWL) price action on the GURU.Markets platform currently stands at 28.56. Werewolf Therapeutics develops innovative anti-tumor agents using PREDATOR technology to precisely target the disease without harming the body. The team consists of top experts attracted by large-scale grants, while the implementation of automated molecule screening systems significantly accelerates the creation of new drug formulas.

HOWL (Werewolf Therapeutics, Inc.) Total Company Value history from 11/23/2025 to 10/28/2026

Werewolf Therapeutics, Inc. - analytical breakdowns and key metrics (HOWL)

- price and consensus price forecast:
Market Price Werewolf Therapeutics Inc.|HOWL - Consensus Target
- market capitalization data:
Market Valuation Werewolf Therapeutics|HOWL - Total Company Value
- book capitalization data:
Net Assets per Single Share Werewolf Therapeutics|HOWL - Company Book Value|Market-to-Book Ratio werewolftx.com|HOWL - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Werewolf Therapeutics|HOWL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Werewolf Therapeutics Inc.|HOWL - Company Debts|Debts to Book Value Werewolf Therapeutics
Fundamental valuation:Werewolf Therapeutics (HOWL)
Original product of Werewolf

Enterprise Value (EV) represents the total acquisition price of a business, summing market capitalization and net debt. Investors utilize this parameter to assess the actual cost of buying an asset, accounting for its liabilities. By analyzing enterprise value levels, one can identify hidden stagnation or a capital accumulation phase. For Werewolf Therapeutics (HOWL), this metric reflects the market valuation of its cytokine platform potential. The stability of this indicator confirms institutional investors' confidence in management's roadmap.

Competitors of Werewolf Therapeutics (HOWL)

IBRX - Total Enterprise Value|IMCR: Real Price to Acquire Entire Company|JANX: Real Price to Acquire Entire Company|Arcus Biosciences, Inc. (RCUS) - Total Company Value|ZYME (zymeworks.com) - Total Company Value|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Immatics Corp IMTX|Business Value Xencor Inc. (XNCR)|Compass Therapeutics - Enterprise Value|replimune.com - Real Price to Acquire Entire Company|LYEL (Lyell Immunopharma, Inc.) - Total Company Value|IPHA: Total Enterprise Value|pyxisoncology.com (PYXS) - Total Company Value|CGEN (Compugen) - Total Company Value|Total Company Value IOBT (IO Biotech, Inc.)|Total Enterprise Value sutrobio.com|INKT: Enterprise Value|Full Takeover Company Value immixbio.com IMMX|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)